Protocol ID
|
Trial Title
|
|---|
| CDR0000257807; JHOC-J0203; NCI-1858; NCT00049088 |
A Phase I Study Of PS-341 In Combination With Docetaxel In Patients With Advanced Solid Tumors |
| CDR0000285625; NCI-03-C-0096; NCI-5748; NCT00057902 |
PS-341 and PS-341 + EPOCH Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas |
| CDR0000068951; E-3200; NCT00025337 |
Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer |
| CDR0000339681; MSKCC-03078; LILLY-H3E-US-JMGA; NCT00072397 |
A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma |
| 6093; H3E-US-JMFE; NCT00040625 |
A Phase II Expanded Access Clinical Trial of Pemetrexed Alone or in Combination with Cisplatin for Patients with Malignant Mesothelioma |
| 7211; H3E-US-JMFX; NCT00061464 |
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial |
| 7221; H3E-US-JMGC; NCT00071136 |
Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer |
| 7771; H3E-MW-JMGJ; NCT00072865 |
A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer |
| 7213; H3E-US-JMFY; NCT00061451 |
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase II Clinical Trial |
| M34101-033; NCT00064610 |
A Phase I/II, Open Label, Dose Escalation Study to Determine the Tolerance and Preliminary Activity of PS-341 Plus Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer Requiring Chemotherapy |
| M34102-049; NCT00051987 |
A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma |
| CDR0000068879; UCCRC-11033; NCI-2630; NCT00023959 |
A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer |
| 6142; H3E-MC-JMEZ; NCT00051493 |
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. |
| CDR0000069282; UAB-0127; UAB-F010806018; NCI-G02-2053; NCT00033423 |
Phase I, Multicenter, Open Label, Dose Escalation Of 90Y-Zevalin Radioimmunotherapy Using A Modified Treatment Regimen For Relapsed Or Refractory CD20+ B-Cell (Follicular/Transformed) Non-Hodgkin's Lymphoma |
| CDR0000068503; MAYO-MC998C; NCI-312; NCT00012298 |
Phase I Study of Two Sequential Doses of IDEC-Y2B8 in Patients With Relapsed Low Grade and Follicular Non-Hodgkin's Lymphoma |
| CDR0000069179; MILL-61896; LIGAND-MILL-61896; NU-IRB-837-002; NCT00030589 |
A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma |
| EMR-008 |
A European Phase I Clinical Trial of Cetuximab in Combination with Cisplatin or Carboplatin, and Different Doses of 5-FU in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| UCLA-0409110-01, JJPRD-26866138-MMY-3002; 26866138-MMY-3002; NCT00111319 |
A Multicenter, International, Randomized, Phase III Clinical Trial of Velcade (Bortezomib) For Injection in Combination with Melphalan and Prednisone Compared to Melphalan and Prednisone Alone in Older Patients with Newly Diagnosed Multiple Myeloma Who Are Not Transplant Candidates |
| EMR 62202-002; NCT00122460 |
A Randomized, Open Label Phase III Clinical Trial of Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil First Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| CDR0000068763, UCLA-0102006, AVENTIS-TAX-GMA-302, BCIRG-006, UAB-0106, UAB-F010326012, NCI-G01-1978, NCT00021255 |
Randomized, Phase III Clinical Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (ACT) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (ACTH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2 Positive Early Breast Cancer Patients |
| CDR0000067138, GOG-0179, ECOG-G0179; NCT00003945 |
Phase III Randomized Study of Cisplatin Only Versus Cisplatin Plus Topotecan Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix |
| CA028; NCT00274443 |
An Open Label Study Treating Subjects With Advanced Non-Small Cell Lung Cancer With ABI-007(Abraxane) in Combination With Carboplatin |
| BO16216; NCT00022672 |
A Randomized, Open-Label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-Free Survival in Patients With HEr2-Positive and Hormone-Receptor Positive Metastatic Breast Cancer |
| NSABP FB-AX-003; NCT00110695 |
A Phase II Trial of Neoadjuvant Chemotherapy With Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer |
| EMR 62202-013; NCT00154102 |
Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan (FOLFIRI) as First-Line Treatment for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Cancer |
| GISMM2001-A; NCT00232934 |
Multicenter, Prospective, Open Label, Randomized Phase III Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65. |
| 20025404; NCT00034346 |
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) |
| CDR0000257266; UCLA-0203073; IMMUNEX-054.0009; NCI-G02-2115; NCT00047151 |
Phase II Study of Monoclonal Antibody ABX-EGF, Irinotecan, Leucovorin Calcium, and Fluorouracil in Patients With Metastatic Colorectal Cancer |
| CAMN107A2103; NCT00135005 |
A Phase I Multicenter, Dose Escalation Study of AMN107 in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) |
